Targeting vector to the urokinase plasminogen activator...

Details Targeting vector to the urokinase plasminogen activator... Targeting vector to the urokinase plasminogen activator...

2006-11-07

2006-11-07

Li, Q. Janice (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S320100, C435S069100

Reexamination Certificate

active

07132405

ABSTRACT:
The present invention relates to the targeted delivery of a delivery vehicle construct which specifically binds to and stimulates endocytosis into cells expressing the urokinase plasminogen activator receptor (uPAR), and particularly human airway epithelia. The delivery vehicle construct comprises a portion of uPA and a cargo linked thereto and is useful for the targeted delivery of the cargo to a cell. In one aspect of the invention, the uPA portion of the delivery vehicle construct comprises the wild-type uPA, a fragment of uPA which has the PAI-1 binding region deleted, or a uPA peptide comprising amino acids 13–19 and is useful for the targeted delivery of the cargo to cells, and in particular to airway epithelia. The present invention also provides a method for delivering the delivery vehicle construct to a cell. The method comprises the steps of (a) contacting a target cell with a delivery vehicle construct comprising a uPA portion and a cargo portion; and (b) obtaining a desired result in the target cell.

REFERENCES:
patent: 5550213 (1996-08-01), Anderson et al.
patent: 5656269 (1997-08-01), Haigwood et al.
patent: 5679350 (1997-10-01), Jankun et al.
patent: 5679782 (1997-10-01), Rosenberg et al.
patent: 5759542 (1998-06-01), Gurewich
patent: 5882877 (1999-03-01), Gregory et al.
patent: 5891664 (1999-04-01), Dan.o slashed et al.
patent: 5942492 (1999-08-01), Jones et al.
patent: 5980886 (1999-11-01), Kay et al.
patent: 6086870 (2000-07-01), Welsh
patent: 6287857 (2001-09-01), O'Riordan et al.
patent: 6649597 (2003-11-01), Welsh et al.
patent: WO 90/12091 (1990-10-01), None
patent: WO 97/05257 (1997-02-01), None
patent: WO 98/46632 (1998-10-01), None
patent: WO 98/46781 (1998-10-01), None
Teramoto et al, J Virol 1998;72:8904-12.
Dichek et al, Circulation 1996;93:301-9.
Handley et al, J Virol 1996;70:4451-6.
Verma et al, Nat. Sep. 1997; 389:239-242.
Makrides et al, Protein Exp Pur. 1999; 17:183-202.
Zink et al, Gene Ther Mol Biol Jan. 2001;6:1-24.
Drapkin PT, O'Riordan CR, Yi SM, Chiorini JA, Cardella J, Zabner, J, Welsh MJ (2000). Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia.J. Clin Invest105:589-596.
Walters R W, Duan D, Engelhardt JF, Welsh MJ (2000). Incorporation of adeno-associated virus in a calcium phosphate coprecipitate improves gene transfer too airway epithelia in vitro and in vivo.J. Virol. 74(1):535-540.
Boucher RC. Status of gene therapy for cystic fibrosis lung disease.J Clin Invest1999 103:441-445.
Chiorini JA, Kim F, Yang L, Kotin RM (1999). Cloning and characterization of adeno-associated virus type 5.J. Virol73(2):1309-1319.
Drapkin et al. (1999). Targeting adenovirus binding to the apical membrane of human airway epithelia. Thirteenth Annual North American Cystic Fibrosis Conference.Pediatr. Pulmonol.Suppl. 19:224 (Abstract 211).
Drapkin et al. (1999). Targeting adenovirus binding to the apical membrane of human airway epithelia.American Society of Gene Therapy,2nd Annual Meeting, Jun. 9-13, 1999. Washington, D.C., Abstract 753.
Hattori N, Sisson TH, Xu Y, Desai TJ, Simon RH. Participation of urokinase-type plasminogen activator receptor in the clearance of fibrin from the lung.Am J Physiol1999 277(3 Pt 1):L573-L579.
Hattori N, Sisson TH, Xu Y, Simon RH. Upregulation of fibrinolysis by adenovirus-mediated transfer of urokinase-type plasminogen activator genes to lung cells in vitro and in vivo.Hum Gene Ther1999 10:215-222.
Lee JH, Zabner J, Welsh MJ (1999). Delivery of an adenovirus vector in a calcium phosphate corprecipitate enhances the therapeutic Index of gene transfer to airway epithelia.Hum. Gene Ther. 10:603-613.
O'Riordan CR, Lachapelle A, Delgado C, Parkes, V, Wadsworth SC, Smith AE, Francis GE (1999). PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.Hum Gene Ther. 10:1349-1358.
Vilhardt F Nielsen M, Sandvig K, van Deurs B (1999). Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized Madin-Darby canine kidney epithelial cells.Mol. Biol. Cell10(1):179-195.
Waltes RW, Grunst T, Bergelson JM, Finberg RW, Welsh MJ, Zabner J (1999). Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia.J Biol. Chem. 274(15):10219-10226.
Walters R, Welsh M (1999). Mechanism by which calcium phosphate coprecipitation enhances adenovirus-mediated gene transfer.Gene Ther6(11):1845-1850.
Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA (1999). A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling.J. Cell Biol. 144(6):1285-1294.
Duan D, Yue Y, Yan Z, McCray PB Jr., Engelhardt JF (1998). Polarity influences the efficiency of recombinant adenoassociated virus infection in dirfferentiated airway epithelia.Hum. Gene Ther. 9(18):2761-2776.
Fasbender A, Lee JH, Walters RW, Moninger TO, Zabner J, Welsh M (1998). Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo.J. Clin. Invest. 102(1):184-193.
Middleton PG, Alton EW (1998). Gene therapy for cystic fibrosis: which postman, which box?Thorax53(3):197-199.
Pickles RJ, McCarty D, Matsui H, Hart PJ, Randell SH, Boucher RC (1998). Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer.J. Virol. 72(7):6014-6023.
Quax PH, Grimbergen JM, Lansink M, Bakker AH, blatter MC, Belin D, van Hinsbergh VW, Verheiien JH (1998). Binding of human urokinase-type plasminogen activator to its receptor.Arterioscler. Thromb. Vasc. Biol. 18(5):693-701.
Rodenberg et al., (1998). Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors α2-macroglobulin receptor/low-density liproprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.Biochem J.329:55-63.
Summerford C, Samulski RJ (1998). Membrane-associate heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.J. Virol.72(2):1438-1445.
Teramato et al. (1998). Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: comparison with adenovirus vectors.J. Virol.72:8904-8912.
Wang G. Davidson BL, Melchert P, Slepushkin VA, van Es HH, Bodner M, Jolly DJ, McCray PB Jr. (1998). Influence of cell polarity on retrovirus-mediated gene transfer to differentiated human airway epithelia.J. Virol.72(12):9818-9826.
Bergelson JM, Cunningham JA, Droguett, G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5.Science275(5304):1320-1323.
Bürgle M, Koppitz M, Riemer C, Kessler H, Konig B, Weidle UH, Kellerman J, Lottspeich F, Graeff H, Schmitt M, Goretzki L, Reuning U, Wilhelm O, Magdolen V (1997). Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.Biol. Chem.78(3-4):231-237.
Czekay RP, Orlando RA, Woodward L, Lundstrom M, Farquhar (1997). Endocytic trafficking of megalin/RAP complexes: dissociation of the complexes in late endosomes.Mol. Biol. Cell8(3):517-532.
Fasbender A, Zabner J, Zeiher BG, Welsh MJ (1997). A low rate of cell proliferation and reduced DNA uptake limit cationic lipid-mediated gene transfer to primary cultures of ciliated human airway epithelia.Gene Ther.4(11):1173-1180.
Goldman CK, Soroceanu L, Smith N, gillespie GY, Shaw W, Burgess S, Bilbao G, Curiel DT (1997). In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer.Nat. Biotechnol.15(5):462-466.
Goretzki L, Mueller BM (1997). Receptor-mediated endocytosis of urokinase-type plasminogen activator is regulated by cAMP-dependent protein kinase.J. Cell Sci.110(PT12):1395-1402.
Kost TA, Ignar DM, Clay WC, Andrews J, Leray JD, Overton L, Hoffman CR, Kilpatrick KE, Ellis B, Emerson DL. Production of a urokinase plasmi

Affiliated with

Also associated with

Rating

Targeting vector to the urokinase plasminogen activator... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeting vector to the urokinase plasminogen activator..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeting vector to the urokinase plasminogen activator... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3641820